1. Oncotarget. 2013 Sep;4(9):1507-26.

Selective anticancer agents suppress aging in Drosophila.

Danilov A(1), Shaposhnikov M, Plyusnina E, Kogan V, Fedichev P, Moskalev A.

Author information: 
(1)Institute of Biology, Komi Science Center, Russian Academy of Sciences,
Syktyvkar, 167982, Russia.

Mutations of the PI3K, TOR, iNOS, and NF-κB genes increase lifespan of model
organisms and reduce the risk of some aging-associated diseases. We studied the
effects of inhibitors of PI3K (wortmannin), TOR (rapamycin), iNOS (1400W), NF-κB 
(pyrrolidin dithiocarbamate and QNZ), and the combined effects of inhibitors:
PI3K (wortmannin) and TOR (rapamycin), NF-κB (pyrrolidin dithiocarbamates) and
PI3K (wortmannin), NF-κB (pyrrolidine dithiocarbamates) and TOR (rapamycin) on
Drosophila melanogaster lifespan and quality of life (locomotor activity and
fertility). Our data demonstrate that pharmacological inhibition of PI3K, TOR,
NF-κB, and iNOS increases lifespan of Drosophila without decreasing quality of
life. The greatest lifespan expanding effect was achieved by a combination of
rapamycin (5 μM) and wortmannin (5 μM) (by 23.4%). The bioinformatic analysis
(KEGG, REACTOME.PATH, DOLite, and GO.BP) showed the greatest aging-suppressor
activity of rapamycin, consistent with experimental data.

DOI: 10.18632/oncotarget.1272 
PMCID: PMC3824538
PMID: 24096697  [Indexed for MEDLINE]